ABSSSI is defined as a bacterial infection of Skin with a lesion size area of ≥75 cm2. ABSSSIs consist of the most frequently diagnosed skin infections worldwide.

1. Acute Bacterial
Skin and
Skin-Structure
Infection
(ABSSSI)
Market Insights, Epidemiology
and Market Forecast- 2028

2. Acute Bacterial Skin
and Skin-Structure Infection
01 0402 03
ABSSSI is defined as a
bacterial infection of Skin
with a lesion size area of
≥75 cm2. ABSSSIs consist
of the most frequently
diagnosed skin infections
worldwide.
There are several
pathogens that lead to
ABSSSIs like Methicillin
sensitive Staphylococcus
aureus, Methicillin
resistant Staphylococcus
aureus, Beta-hemolytic
Streptococcus, Escherichia
coli and many others.
ABSSSIs may be either
community-acquired or
hospital-acquired, and
the predisposing factors
include trauma, chronic
cutaneous lesions, skin
conditions, edema due to
venous insufficiency, and
immunosuppression.
The serious ABSSSIs that
need hospitalization for
parenteral antibiotic
therapy are identified
based on the nature of
the potential causative
pathogens and host
factors pointing to the
severity of the disease.
DelveInsight © 2019 | All rights reserved

3. In the United States, more than 15 million bacterial
skin and skin structure infections occur.
1
ABSSSI Epidemiology
Acute Bacterial Skin and Skin Structure Infections
total 7MM Incident cases were 7,259,777 in 2017.
2
There were 1,942,229 male patients and 1,406,442
female cases suffering from ABSSSI in 2017 in the
United States.
3
A total of 1.8% of hospital admissions for 2005 to
2011 were for adult patients with a SSSI primary
diagnosis.
4
DelveInsight © 2019 | All rights reserved

4. ABSSSI Market Outlook
ABSSSI treatment is quite difficult, as
there is an increased antimicrobial
resistance b between Gram-positive and
Gram-negative bacteria with methicillin-
resistant, but the treatment continues to
be antimicrobial therapies combined
with appropriate surgical intervention.
Oral and intravenous options for
ABSSSI treatment for activity against
Methicillin resistant Staphylococcus
aureus (MRSA), include several long-
standing therapies, such as
sulfamethoxazole-trimethoprim,
clindamycin and many others.
ABSSSI treatment usually includes an
antimicrobial therapy, surgical drainage,
and antibiotic therapy. The therapeutic
approaches favored in treating skin
infections include adjunctive therapies,
early and appropriate empiric antibiotic
therapy, wound culture with
susceptibility testing and surgical
drainage and debridement.
The major subtype of ABSSSI is
cellulitis for which the treatment
involves an oral antibiotic with
activity against streptococci. Major
treatment options for mild cases of
non-purulent infections include
penicillin, amoxicillin, amoxicillin-
clavulanate, dicloxacillin, cephalexin,
and clindamycin.
DelveInsight © 2019 | All rights reserved

5. Drug- Ceftobiprole
medocaril
Company- Basilea
Pharmaceutica
ABSSSI Emerging
Drugs and Companies
Drug- Sodium Fusidate
Company- Arrevus
Drug- Iclaprim
Company- Motif Bio
Drug- Brilacidin
Company- Innovation Pharmaceutica
DelveInsight © 2019 | All rights reserved

6. Complete Information
For complete information on
ABSSSI Market Insights, Epidemiology and Market Forecast-2028
please click the link below
Click here
OR
Write Us At
info@delveinsight.com
DelveInsight © 2019 | All rights reserved

7. DelveInsight is a premier
Business Consulting and Market
Research firm focused exclusively
on the life science segment. With
a wide array of smart end-to-
end solutions, the firm helps the
global Pharmaceutical and Bio-
Tech companies formulate
prudent business decisions for
improving their performances to
stay ahead of the competitors.
ABOUT
MISSION
To provide “insights across the
value chain” and helping the
organization to take a prudent
business decision through the
use and analysis of actionable
market intelligence. The mission
also is to provide the most
effective result and efficient
service with utmost client care
for maintaining a long-term
relationship with them.
To be the most trusted market
research & business
consulting firm in the world;
and to continue enable the
Pharma & Bio-Tech companies
to achieve their goals with the
best strategic insight and
competitive solution. The
vision also is inclusive of
becoming a one-stop solution
provider for the entire gamut
of drug development process.
VISION
MISSION
About DelveInsight
DelveInsight © 2019 | All rights reserved

8. DelveInsight is a premier Business
Consulting and Market Research firm
focused exclusively on the life science
segment. With a wide array of smart end-
to-end solutions, the firm helps the
global Pharmaceutical and Bio-Tech
companies formulate prudent business
decisions for improving their
performances to stay ahead of the
competitors.
ABOUT
To provide “insights across the value
chain” and helping the organization to
take a prudent business decision through
the use and analysis of actionable market
intelligence. The mission also is to provide
the most effective result and efficient
service with utmost client care for
maintaining a long-term relationship with
them.
MISSION
To be the most trusted market research
& business consulting firm in the
world; and to continue enable the
Pharma & Bio-Tech companies to
achieve their goals with the best
strategic insight and competitive
solution. The vision also is inclusive of
becoming a one-stop solution provider
for the entire gamut of drug
development process.
VISION
About DelveInsight
DelveInsight © 2019 | All rights reserved

9. Service Offerings by
DelveInsight
1 FORECASTING
PIPELINE
CONSULTING
MARKET
INTELLIGENCE
OPPORTUNITY
ASSESSMENT
REPORT STORE
COMPETITIVE
ANALYSIS
PHARMDELVE
2
3
4
5
6
7
8
DelveInsight © 2019 | All rights reserved

10. Contact Us
DelveInsight © 2019 | All rights reserved
info@delveinsight.com
+91-11-4568 9769
www.delveinsight.com
blog/delveInsight/
twitter/delveInsight
LinkedIn/delveInsight

11. THANK YOU